Search results
Results From The WOW.Com Content Network
Valneva along with Dynavax Technologies [11] developed a candidate inactivated whole virus vaccine against COVID-19, VLA2001, [12] derived from its Ixiaro Japanese encephalitis vaccine, which underwent a Phase 1/2 trial in the United Kingdom.
"PBM reform is top of mind with legislators," Victor Bulto, president of Novartis' U.S. operations said in an interview this week during the JP Morgan Healthcare Conference in San Francisco.
(Reuters) -Swiss drugmaker Novartis said on Saturday it had received a binding offer from Germany's Siemens Healthineers to acquire its molecular imaging business for Fluorine-18 positron emission ...
Swiss drugmaker Novartis on Friday said it had sued the U.S. government in an attempt to halt the Medicare drug-price negotiation program, which includes its top-selling heart-failure medicine ...
It uses the same manufacturing technology as Valneva's Ixiaro vaccine for Japanese encephalitis. [1] History. Clinical trials. ...
(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according ...
Japanese encephalitis vaccines first became available in the 1930s. [3] One of them was an inactivated mouse brain-derived vaccine (the Nakayama and/or Beijing-1 strain), made by BIKEN and marketed by Sanofi Pasteur as JE-VAX, until production ceased in 2005.
FRANKFURT (Reuters) -Novartis said its experimental drug atrasentan was shown to have a positive effect on an indicator of kidney health in people suffering from a rare type of kidney disease in ...